when

Latest
Archive

by source

All Sources
Sources Page

department

Clinical
Regulatory
Medical Affairs
Commercial
R&D / Discovery
Biostatistics / Data
Manufacturing / CMC
Market Access

therapeutic area

Oncology
Immunology
Neuroscience
Cardiovascular
Metabolic
Rare Disease
Infectious Disease

location & type

Remote Only
US Only
California
Massachusetts
Internships
Phase 3 Roles
All Jobs →

Sign In Subscribe

pharmadog

fetch the data · sniff the signal

Discover

Jobs
News

Hubs

Topics
Patent cliff
Publications

Tools

Compare
Search
Bookmarks

Trust

About
Sources
Contact

Legal

Privacy
Terms
Pricing

© 2026 pharmadog.xyz

made by humans and a good dog

home
jobs
news
search

Antibody-Drug Conjugate (ADC) · news · pharmadog

← back to Antibody-Drug Conjugate (ADC)

News · Antibody-Drug Conjugate (ADC)

132 stories

May 8, 26Dr Sznol on the Nuances of Recommending Neoadjuvant Therapy in Metastatic Melanomaonclive

May 8, 26Biomarker-Directed Therapies Move the GI Oncology Paradigm Beyond a One-Size-Fits-All Approach: With Michael J. Pishvaian, MD, PhDonclive

May 8, 26Capivasertib/Fulvestrant Yields Numerical OS Advantage in PIK3CA/AKT1/PTEN–Altered Breast Canceronclive

May 8, 26FDA Approves Zenocutuzumab for NRG1 Fusion+ Cholangiocarcinomaonclive

May 8, 26Daiichi Sankyo posts 'extraordinary loss' of nearly $1Bendpoints

May 8, 26UT MD Anderson Shares Latest Research Breakthroughsonclive

May 8, 26Giants of Cancer Care Announces the 14th Annual Class of Inducteesonclive

May 8, 26OncLive Weekly News Quiz (5/8/2026): Test Your Knowledge on Key Breast, Lung, and Pancreatic Cancer Updatesonclive

May 8, 26OncLive Polls Reveal Picks for Top Lung Cancer Abstracts at ASCO 2026onclive

May 8, 26Poll Results Highlight Breast Cancer Abstracts of Interest at ASCO 2026onclive

May 8, 26Dr Gruenbaum on Where Alternative Options to BTK Inhibitors Stand in MCLonclive

May 8, 26Cumulative ADC Toxicities and Closing Reflections: Managing Edema, Fatigue, and Optimizing Long-Term Tolerabilityonclive

May 8, 26Natalie Holles' next move after Third Harmonic shutdown; Mark Alles passes the torch at ADC biotechendpoints

May 7, 26Dr Sznol on Optimal Treatment Sequencing in Melanomaonclive

May 7, 26Dr Mauro on the Significance of Alternative TKI Formulations in CMLonclive

May 7, 26Dr Olawaiye on the FDA Approval of Relacorilant Plus Nab-Paclitaxel in PROConclive

May 7, 26Sylvester Comprehensive Cancer Center Identifies a Screening Gap to Prevent a Type of Leukemia in the U.S.onclive

May 7, 26ASCO 2026 TNBC Deep Dive: Breast Cancer Experts Preview Practice-Informing Studiesonclive

May 7, 26Track the Lung Cancer Abstracts That are Gaining Attention at ASCO 2026onclive

May 7, 26Reigniting Your Curiosity During Fellowshiponclive

May 6, 26Dr McGregor on the DAD-IO Trial of Sacituzumab Govitecan and EV in Metastatic Urothelial Carcinomaonclive

May 6, 26Neoadjuvant T-DXd Followed by THP Improves RCB in HER2+ Breast Canceronclive

May 6, 26Dr Lee on Research Collaborations Studying PD-L1 as a Biomarker in NSCLConclive

May 6, 26Dr Chari on Frontline Combinations and Transplant Approaches in Multiple Myelomaonclive

May 6, 26Lonza looks to ride ADC wave with upcoming factory, workforce expansionendpoints

May 6, 26Cases and Conversations™: Next-Generation Pathology Advances and Considerations for Precision Care in Non–Small Cell Lung Canceronclive

May 6, 26Dr Herrera on the Significance of the FDA Approval of Nivolumab Plus AVD for Classical Hodgkin Lymphomaonclive

May 6, 26Dr Sznol on Biomarkers of Response in Metastatic Melanomaonclive

May 6, 26Transformational Utah Investment in Artificial Intelligence and Computing to Advance Health and Discoveryonclive

May 6, 26ASCO 2026 HR+ and HER2+ Breast Cancer Preview: Read up on the Insights to Know Before You Goonclive

← prevpage 4 of 5next →